We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-1.15%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.35B
AUM Growth
-$460M
(-16%)
Cap. Flow
-$294M
Cap. Flow
% of AUM
-12.51%
Top 10 Holdings %
Top 10 Hldgs %
32.94%
Holding
105
New
18
Increased
28
Reduced
25
Closed
20
Top Buys
| 1 |
Perspective Therapeutics
CATX
|
+$43.9M |
| 2 |
Cullinan Oncology
CGEM
|
+$33.2M |
| 3 |
Incyte
INCY
|
+$30M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$24.9M |
| 5 |
argenx
ARGX
|
+$23.2M |
Top Sells
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$139M |
| 2 |
Align Technology
ALGN
|
+$62M |
| 3 |
Boston Scientific
BSX
|
+$57.5M |
| 4 |
Eli Lilly
LLY
|
+$54.5M |
| 5 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$46.6M |
Sector Composition
| 1 | Healthcare | 99.8% |
| 2 | Technology | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Intuitive Surgical
ISRG
$138B
| $109M | 4.63% |
245,000
+19,000
| +8% | +$7.57M |
|
|
2
Boston Scientific
BSX
$64B
| $90.1M | 3.83% |
1,170,100
-785,900
| -40% | -$57.5M |
|
3
Natera
NTRA
$39.7B
| $83M | 3.53% |
766,500
-36,800
| -5% | -$3.74M |
|
4
Arvinas
ARVN
$534M
| $79.5M | 3.38% |
2,987,845
+2,655
| +0.1% | +$84.6K |
|
5
Acadia Healthcare
ACHC
$2.97B
| $75.6M | 3.21% |
1,120,000
+115,000
| +11% | +$8.03M |
|
6
Dianthus Therapeutics
DNTH
$5.46B
| $75.5M | 3.21% |
2,917,231
+199,677
| +7% | +$4.8M |
|
7
Syndax Pharmaceuticals
SNDX
$2.08B
| $68.5M | 2.91% |
3,335,000
+922,500
| +38% | +$19.3M |
|
8
Neurocrine Biosciences
NBIX
$17.3B
| $67.6M | 2.87% |
491,000
-45,500
| -8% | -$6.24M |
|
9
Avantor
AVTR
$7.65B
| $65.4M | 2.78% |
3,086,000
+391,000
| +15% | +$9.42M |
|
10
Cigna
CI
$78.8B
| $61M | 2.59% |
184,500
| – | – |
|
11
Jazz Pharmaceuticals
JAZZ
$15B
| $58.1M | 2.47% |
544,500
-39,500
| -7% | -$4.34M |
|
12
Alnylam Pharmaceuticals
ALNY
$37.3B
| $53.9M | 2.29% |
222,000
-21,000
| -9% | -$3.32M |
|
13
Regeneron Pharmaceuticals
REGN
$69.7B
| $50.4M | 2.14% |
48,000
-20,000
| -29% | -$19.4M |
|
14
Illumina
ILMN
$28.3B
| $49.9M | 2.12% |
478,000
+905
| +0.2% | +$102K |
|
15
Tenet Healthcare
THC
$16.6B
| $49.5M | 2.1% |
372,000
-229,000
| -38% | -$27.6M |
|
16
AbbVie
ABBV
$431B
| $47.6M | 2.02% |
277,800
+50,800
| +22% | +$8.41M |
|
|
17
Thermo Fisher Scientific
TMO
$199B
| $44.2M | 1.88% |
80,000
+43,400
| +119% | +$24.9M |
|
18
Structure Therapeutics
GPCR
$3.53B
| $42.2M | 1.79% |
1,075,000
+211,000
| +24% | +$8.66M |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $41.3M | 1.75% |
383,000
-43,000
| -10% | -$4.3M |
|
20
CG Oncology
CGON
$6.44B
| $40.9M | 1.74% |
1,296,225
-158,540
| -11% | -$5.5M |
|
21
Merck
MRK
$305B
| $40.2M | 1.71% |
325,000
-177,000
| -35% | -$22.8M |
|
22
Ultragenyx Pharmaceutical
RARE
$3.12B
| $39.5M | 1.68% |
960,000
+26,500
| +3% | +$1.13M |
|
23
IDEAYA Biosciences
IDYA
$3.54B
| $39.2M | 1.67% |
1,117,000
+317,300
| +40% | +$12.6M |
|
24
Danaher
DHR
$142B
| $37.5M | 1.59% |
150,000
+6,200
| +4% | +$1.57M |
|
25
Janux Therapeutics
JANX
$978M
| $35.2M | 1.5% |
840,219
+455,974
| +119% | +$21.4M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH